Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Utilizing TP53 hotspot mutations as effective predictors of gemcitabine treatment outcome in non-small-cell lung cancer.
Cell Death Discov
January 2025
Institute of Biopharmaceutical Sciences, College of Pharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan.
TP53 mutations are recognized to correlate with a worse prognosis in individuals with non-small cell lung cancer (NSCLC). There exists an immediate necessity to pinpoint selective treatment for patients carrying TP53 mutations. Potential drugs were identified by comparing drug sensitivity differences, represented by the half-maximal inhibitory concentration (IC50), between TP53 mutant and wild-type NSCLC cell lines using database analysis.
View Article and Find Full Text PDFReturn to duty after non-surgical treatment of a non-neurological thoracic or lumbar spine fracture in French military patients: a retrospective analysis of 54 patients.
BMJ Mil Health
January 2025
Ecole du Val-de-Grace, Paris, France
Introduction: Non-surgical management of non-neurological thoracic or lumbar spine (TL) fractures seems to provide good results in the civilian population, leading to return to work in most cases. However, data on the military population are limited, particularly regarding return to duty. This study aimed to describe a population of French military patients with traumatic non-neurological TL fractures and the outcomes of non-surgical management regarding operational capacity.
View Article and Find Full Text PDFA year in review: new treatments and expanded indications in dermatology in 2024.
J Dermatolog Treat
December 2025
Center for Translational Dermatology, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Methods: A literature search was conducted on Drugs@FDA: FDA-Approved Drugs for the year 2024 to identify new dermatologic treatments.
Results: In 2024, the FDA approved seven new dermatologic therapies and expanded the indications for seven current therapies. These therapies treat conditions such as atopic dermatitis, hidradenitis suppurativa, prurigo nodularis, molluscum contagiosum, and alopecia areata, among others.
Dislocation is the second most common indication for revision total hip arthroplasty (THA). In revision cases the dislocation rate can be as high as 5-30%. The aim of this study was to assess the outcome, specifically the dislocation rate in revision THA where a dual mobility cup was used.
View Article and Find Full Text PDFRemote neurodegeneration in the lumbosacral cord one month after spinal cord injury: a cross-sectional MRI study.
Ann Clin Transl Neurol
January 2025
Department of Neuro-Urology, Balgrist University Hospital, University of Zürich, Zürich, Switzerland.
Objective: To characterize structural integrity of the lumbosacral enlargement and conus medullaris within one month after spinal cord injury (SCI).
Methods: Lumbosacral cord MRI data were acquired in patients with sudden onset (<7 days) SCI at the cervical or thoracic level approximately one month after injury and in healthy controls. Tissue integrity and loss were evaluated through diffusion tensor (DTI) and T2*-weighted imaging (cross-sectional area [CSA] measurements).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!